FDA Grants AP Status for Desogestrel and Ethinyl Estradiol ANDA219670
The FDA has granted Abbreviated Approval (AP) status for ANDA219670, a combination of Desogestrel and Ethinyl Estradiol.
Asset / Drug
Drug and asset intelligence for Desogestrel with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.